GAIASO Theranostics is an innovative company focused on transforming the diagnosis and treatment of female cancers through radioligand-based theranostics.
Emerging from a collaboration between Navigo Proteins GmbH and PreMIT Pty Ltd (an affiliate of the Melbourne Theranostic Innovation Centre), GAIASO unites a team of globally recognised experts. By leveraging cutting-edge platforms such as Affilin® protein engineering, GAIASO is developing a new generation of theranostic agents. These innovations harness the full potential of radiotherapy through deeper biological understanding of therapeutic targets, tunable biodistribution, and rational combination therapies designed to enhance radiation response.
Female cancers are often aggressive and progress to improve outcomes is urgently required. GAIASO’s team is determined to accelerate and deliver life-saving options for more women around the world.
Company Details
- Employees
- 2
- Founded
- -
- Address
- 14-20 Blackwood St, Level 8,australia
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- to cancer care.
- HQ
- North Melbourne, Victoria
Gaiaso Theranostics Questions
Gaiaso Theranostics's website is https://www.gaiasotheranostics.com/
Gaiaso Theranostics's LinkedIn profile is https://au.linkedin.com/company/gaiaso-theranostics
Gaiaso Theranostics has
2 employees.
View email and phone details for 2
employees at Gaiaso Theranostics.
Gaiaso Theranostics's industry is
Biotechnology Research
Gaiaso Theranostics's top competitors are
Sinovation Medical,
Medical Mission Aid Ltd,
The Concordia Initiative,
Navigo Proteins Gmbh,
Melbourne Theranostic Innovation Centre,
Epic Theranostics,
Premit Pty Ltd,
Atomic Oncology,
Protherium,
Mercury Me Dmcc.
Gaiaso Theranostics's categories are Biotechnology Research
Gaiaso Theranostics's founding year is 2025
